[go: up one dir, main page]

MX2009003017A - Heterociclos sustituidos que contienen nitrogeno como inhibidores del receptor adp plaquetario. - Google Patents

Heterociclos sustituidos que contienen nitrogeno como inhibidores del receptor adp plaquetario.

Info

Publication number
MX2009003017A
MX2009003017A MX2009003017A MX2009003017A MX2009003017A MX 2009003017 A MX2009003017 A MX 2009003017A MX 2009003017 A MX2009003017 A MX 2009003017A MX 2009003017 A MX2009003017 A MX 2009003017A MX 2009003017 A MX2009003017 A MX 2009003017A
Authority
MX
Mexico
Prior art keywords
receptor inhibitors
nitrogen containing
adp receptor
platelet adp
containing substituted
Prior art date
Application number
MX2009003017A
Other languages
English (en)
Inventor
Anjali Pandey
Shawn M Bauer
Robert M Scarborough
Original Assignee
Portola Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc
Publication of MX2009003017A publication Critical patent/MX2009003017A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/20—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 4
    • C07D265/22—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente invención se refiere a compuestos los cuales son empleados como inhibidores del receptor ADP plaquetario, para tratar trombosis y para reducir la probabilidad y/o severidad de un evento isquémico secundario en un paciente.
MX2009003017A 2006-09-20 2007-09-20 Heterociclos sustituidos que contienen nitrogeno como inhibidores del receptor adp plaquetario. MX2009003017A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84632806P 2006-09-20 2006-09-20
US11/856,616 US7834023B2 (en) 2006-09-20 2007-09-17 Substituted dihydroquinazolines as platelet ADP receptor inhibitors
PCT/US2007/079076 WO2008036843A2 (en) 2006-09-20 2007-09-20 Nitrogen containing substituted heterocycles as platelet adp receptor inhibitors

Publications (1)

Publication Number Publication Date
MX2009003017A true MX2009003017A (es) 2009-06-08

Family

ID=39048759

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009003017A MX2009003017A (es) 2006-09-20 2007-09-20 Heterociclos sustituidos que contienen nitrogeno como inhibidores del receptor adp plaquetario.

Country Status (16)

Country Link
US (2) US7834023B2 (es)
EP (1) EP2094272B1 (es)
JP (1) JP5266232B2 (es)
KR (1) KR20090057314A (es)
AU (1) AU2007299723A1 (es)
BR (1) BRPI0718444A2 (es)
CA (1) CA2664411A1 (es)
CO (1) CO6160324A2 (es)
IL (1) IL197726A0 (es)
MA (1) MA30775B1 (es)
MX (1) MX2009003017A (es)
NO (1) NO20091331L (es)
NZ (1) NZ576162A (es)
RU (1) RU2009114827A (es)
TN (1) TN2009000091A1 (es)
WO (1) WO2008036843A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100260825A1 (en) * 2009-04-13 2010-10-14 Nair Madhavan G Antifolates for the treatment of cardiovascular, inflammatory, neoplastic, autoimmune and related diseases in sublingual dosage units, film strips, or skin patches
PH12013502611A1 (en) 2011-06-24 2014-04-28 Amgen Inc Trpm8 antagonists and their use in treatments
MX2013015058A (es) 2011-06-24 2014-01-20 Amgen Inc Antagonistas de melastatina 8 de potencial receptor transitorio y su uso en tratamientos.
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
US9724351B2 (en) 2012-08-23 2017-08-08 Alios Biopharma, Inc. Compounds for the treatment of paramoxyvirus viral infections
CA2988572A1 (en) 2015-06-26 2016-12-29 Takeda Pharmaceutical Company Limited 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor
WO2017069173A1 (ja) 2015-10-20 2017-04-27 武田薬品工業株式会社 複素環化合物
WO2019213160A1 (en) 2018-04-30 2019-11-07 Unity Biotechnology Acyl phosphonamidates and acyl benzylamines that are bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL135175B2 (en) * 1983-12-22 1985-10-31 Method of printing of articles made of polyamide fibres
DE19650975A1 (de) * 1996-12-09 1998-06-10 Basf Ag Neue heterocyclisch substituierte Benzamide und deren Anwendung
TR200103336T2 (tr) 1999-03-17 2002-04-22 Astrazeneca Ab Amid türevleri.
US6906063B2 (en) * 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
FR2837201A1 (fr) * 2002-03-18 2003-09-19 Servier Lab Nouveaux composes derives de la quinazoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP2005097276A (ja) * 2003-08-22 2005-04-14 Takeda Chem Ind Ltd 縮合ピリミジン誘導体およびその用途
CA2540214A1 (en) 2003-10-03 2005-04-14 Portola Pharmaceuticals, Inc. 2,4-dioxo-3-quinazolinylaryl sulfonylureas
KR20060113699A (ko) * 2003-10-03 2006-11-02 포톨라 파마슈티컬스, 인코포레이티드 치환된 이소퀴놀리논
KR20070028536A (ko) 2004-06-15 2007-03-12 아스트라제네카 아베 항암제로서의 치환된 퀴나졸론
US20070010537A1 (en) * 2004-08-20 2007-01-11 Kazumasa Hamamura Fused pyramidine derivative and use thereof
ZA200702688B (en) 2004-09-29 2008-06-25 Portola Pharm Inc Substituted 2H-1,3-benzoxazin-4-(3H)-ones
US20100234355A1 (en) 2006-06-19 2010-09-16 Barrie Martin Isoquinoline derivatives and their use as inhibitors of cytokine mediated diseases

Also Published As

Publication number Publication date
CA2664411A1 (en) 2008-03-27
US7834023B2 (en) 2010-11-16
JP5266232B2 (ja) 2013-08-21
EP2094272A2 (en) 2009-09-02
KR20090057314A (ko) 2009-06-04
HK1131058A1 (en) 2010-01-15
BRPI0718444A2 (pt) 2013-11-19
TN2009000091A1 (en) 2010-08-19
CO6160324A2 (es) 2010-05-20
MA30775B1 (fr) 2009-10-01
JP2010504357A (ja) 2010-02-12
IL197726A0 (en) 2009-12-24
AU2007299723A1 (en) 2008-03-27
WO2008036843A2 (en) 2008-03-27
US20080132499A1 (en) 2008-06-05
WO2008036843A3 (en) 2008-05-15
EP2094272B1 (en) 2014-03-26
NO20091331L (no) 2009-05-20
RU2009114827A (ru) 2010-10-27
NZ576162A (en) 2012-03-30
US20110098247A1 (en) 2011-04-28

Similar Documents

Publication Publication Date Title
TN2009000091A1 (en) Nitrogen containing substituted heterocycles as platelet adp receptor inhibitors
NO20083923L (no) Pyrazolkinoloner er potente parp-inhibitorer
TNSN08191A1 (en) Kinase inhibitors
TW200942533A (en) Pyridyl inhibitors of hedgehog signalling
MY146989A (en) Kinase inhibitors
TW200640867A (en) Pyridine-3-carboxamide derivatives as CB1 inverse agonists
TN2010000096A1 (en) Oxadiazole - and oxazole - substituted benzimidazole - and indole - derivatives as dgat1 inhibitors
SG170813A1 (en) New compounds
ATE479687T1 (de) Kinaseinhibitoren
TW200720268A (en) 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors
GB2453058A (en) Kinase antagonists
WO2007120689A3 (en) Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
IN2012DN00572A (es)
EA200900091A1 (ru) Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
WO2007026251A8 (en) Use of dual c-kit/fgfr3 inhibitors for treating multiple myeloma
WO2008009639A3 (en) New indications for direct thrombin inhibitors
MX2009004030A (es) Articulos antimicrobianos y metodos de fabricacion.
NO20091955L (no) Antivirale sammensetninger, og fremgangsmater for anvendelse
WO2007140317A3 (en) Use of inhibitors of cytosolic ph0sph0lipase a2 in the treatment of thrombosis
ZA200801332B (en) Pentacyclic kinase inhibitors
WO2007146813A3 (en) Pyridinone analogs as cell proliferation inhibitors
WO2008092091A3 (en) Mao inhibiting n-benzyl-n-propargyl-amines useful for treating obesity
WO2011033115A3 (en) Compounds useful against kinetoplastideae parasites
WO2008022113A3 (en) Methods for treating rheumatoid arthritis

Legal Events

Date Code Title Description
FG Grant or registration